Ignite Creation Date:
2025-12-24 @ 3:40 PM
Ignite Modification Date:
2025-12-28 @ 5:25 AM
Study NCT ID:
NCT04781192
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2021-02-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Sponsor:
University of Kansas Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2025-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-25
First Submit QC Date:
None
Study First Post Date:
2021-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-22
Last Update Post Date:
2024-02-23
Last Update Post Date Type:
ACTUAL